CAR T Therapy: New Hope for Lymphoma Treatment
- An experimental, next-generation CAR T-cell therapy is offering hope to lymphoma patients who have exhausted other treatment options. A recent study revealed that the "armored" CAR T-cell therapy...
- The findings, spearheaded by researchers at the University of Pennsylvania's Perelman School of Medicine, were published in the New England Journal of Medicine.
- while CAR T-cell therapy has transformed blood cancer treatment, more than half of lymphoma patients do not achieve long-term remission with currently available therapies.
Groundbreaking “armored” CAR T-cell therapy offers important hope for lymphoma patients who have weary other treatment options. This innovative approach led to cancer reduction in 81% of participants, with over half achieving complete remission, marking a pivotal moment in blood cancer treatment. This experimental CAR T-cell therapy, featuring the primary_keyword and designed to boost the immune response, is producing impressive results, including long-term remission for some patients. News Directory 3 is dedicated to bringing you the latest advancements in medical breakthroughs. Researchers are also working on refining the manufacturing process for this promising secondary_keyword. Discover what’s next in lymphoma treatment.
‘Armored’ CAR T-Cell Therapy Shows Promise for Lymphoma Patients
Updated June 18, 2025
An experimental, next-generation CAR T-cell therapy is offering hope to lymphoma patients who have exhausted other treatment options. A recent study revealed that the ”armored” CAR T-cell therapy lead to cancer reduction in 81% of participants, with 52% achieving complete remission. Some of the earliest patients treated have experienced remission for two years or more.
The findings, spearheaded by researchers at the University of Pennsylvania’s Perelman School of Medicine, were published in the New England Journal of Medicine. The study highlights the potential of this novel approach for patients with relapsed or refractory B-cell lymphomas.
while CAR T-cell therapy has transformed blood cancer treatment, more than half of lymphoma patients do not achieve long-term remission with currently available therapies. For those whose cancers return or resist CAR T-cell therapy, few options remain. Retreatment with existing CAR T-cell therapies has proven largely ineffective.
Jakub Svoboda, an associate professor of Hematology-Oncology who directed the clinical trial at penn Medicine’s Abramson Cancer Center, expressed enthusiasm about the results. ”I’m thrilled that this new generation of CAR T cell therapy was highly effective in patients who have already tried everything available,” Svoboda said. He also noted that the toxicity of the new product was comparable to existing commercial CAR T-cell therapies.
The new CAR T cell therapy, called huCART19-IL18, targets the CD19 antigen on lymphoma cells. It is indeed modified to secrete interleukin 18 (IL18), a pro-inflammatory cytokine. This addition enhances the immune system by recruiting additional immune cells to support the engineered T cells, further protecting the CAR T cells and boosting their ability to attack cancer cells, according to Carl June, the Richard W. Vague Professor in Immunotherapy.
The phase I clinical trial involved 21 patients who had received a median of seven prior therapies. All but one had previously undergone CAR T-cell therapy.The addition of IL18 did not cause unexpected safety concerns beyond the known side effects of CAR T-cell therapy, such as cytokine release syndrome (CRS) and neurotoxicity, which were successfully managed.
June believes that incorporating cytokine secretion into CAR T-cell design could have broad implications for enhancing cellular therapies,even beyond blood cancers. ”With longer T cell persistence and expansion, this strategy could be powerful in settings where CAR T hasn’t performed as well, such as solid tumors,” June said.
The production of huCART19-IL18 utilizes a rapid, three-day manufacturing process developed by Penn’s Center for Cellular Immunotherapies. this shortened timeframe allows patients with aggressive cancers to begin therapy sooner than with standard 9- to 14-day manufacturing times. Previous research suggests that this rapid manufacturing may also enhance the potency of the T cells.
what’s next
The research team plans further clinical trials, including studies involving patients with acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Another trial for non-hodgkin’s lymphoma using a similar IL18-armored CAR T-cell product is currently underway. The team is also collaborating with a Penn spinout company to refine the CAR T-cell manufacturing process.